These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 9480119

  • 21. [Preparation of thrombocyte concentrates in the Travenol CS-3000 separator (factors affecting the thrombocyte yield and presence of leukocytes)].
    Bláha M, Varvarovský I, Pecka M, Malý J, Jebavý L, Siroký O.
    Vnitr Lek; 1991 Jan; 37(1):73-9. PubMed ID: 2058100
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. [Thrombocytapheresis with the (Baxter) A 201 cell separator--initial data of biocompatibility].
    Moog R, Luboldt W, Krützfeldt A, Paar D, Holtmann M, Mengelkamp AK.
    Infusionstherapie; 1991 Oct; 18(5):244-7. PubMed ID: 1769738
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Discontinuous automated calcium supplementation during thrombocytapheresis with the haemonetics MCS+ version C.
    Valbonesi M, Bruni R, Florio G, Marghero A, Telani A, Varinelli I.
    Transfus Sci; 2000 Oct; 23(2):165-6. PubMed ID: 11794132
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [Quality control in producing thrombocytapheresis preparations with minimal leukocyte contamination].
    Riggert J, Humpe A, Simson G, Köhler M.
    Beitr Infusionsther Transfusionsmed; 1997 Oct; 34():89-94. PubMed ID: 9417356
    [Abstract] [Full Text] [Related]

  • 32. Discontinuous automated calcium supplementation during thrombocytapheresis with the MCS+ version C. Absence of severe complication due to calcium deprivation in 4308 procedures.
    Valbonesi M, Capra C, Frisoni R, Varinelli I.
    Transfus Apher Sci; 2004 Oct; 31(2):167-8. PubMed ID: 15501421
    [No Abstract] [Full Text] [Related]

  • 33. [Particle formation in disposable systems for the V.50.1 (Haemonetics) cell separator].
    Misterek J, Mueller-Eckhardt C.
    Beitr Infusionsther; 1991 Oct; 28():159-61. PubMed ID: 1725614
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Evaluation of a new apheresis system for the collection of leukoreduced single-donor platelets.
    Zingsem J, Strasser E, Ringwald J, Zimmermann R, Weisbach V, Eckstein R.
    Transfusion; 2007 Jun; 47(6):987-94. PubMed ID: 17524087
    [Abstract] [Full Text] [Related]

  • 37. [Optimizing cell separation with the Cell Separator AS-106].
    Kretschmer V, Rossa C.
    Beitr Infusionsther; 1991 Jun; 28():188-94. PubMed ID: 1725617
    [Abstract] [Full Text] [Related]

  • 38. Quality and safety of platelet apheresis concentrates produced with a new leukocyte reduction system.
    Riggert J, Humpe A, Simson G, Köhler M.
    Vox Sang; 1998 Jun; 74(3):182-8. PubMed ID: 9595646
    [Abstract] [Full Text] [Related]

  • 39. Plateletpheresis: what's new?
    Valbonesi AM, Florio G, Venturino V, Bruni R.
    Transfus Sci; 1996 Dec; 17(4):537-44. PubMed ID: 10168551
    [Abstract] [Full Text] [Related]

  • 40. In vitro evaluation of Haemonetics MCS+ apheresis platelet concentrates treated with photochemical pathogen inactivation following plasma volume reduction using the INTERCEPT Preparation Set.
    Isola H, Kientz D, Aleil B, Laeuffer P, Weil J, Wiesel ML, Laforêt M, Lin L, Mayaudon V, Cazenave JP.
    Vox Sang; 2006 Feb; 90(2):128-30. PubMed ID: 16430671
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.